You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 196001 - 196010 of 207725 results
  1. Novel IL-15 Superagonist Therapy for Bladder Cancer

    SBC: Altor BioScience, LLC            Topic: NCI

    DESCRIPTION (provided by applicant): Non-Muscle Invasive Bladder cancer (NMIBC), the fifth most common cancer in the United States and the costliest to treat per patient of all cancers, tends to recur, requiring repeated intervention and long-term follow-up. NMIBC are usually treated by surgical resection and intravesical chemotherapy and immunotherapy. Immunotherapy usually consists of intrav ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  2. Riluzole Prodrugs for Melanoma and ALS

    SBC: FOX CHASE CHEMICAL DIVERSITY CENTER INC.            Topic: NCI

    DESCRIPTION (provided by applicant): Metastatic melanoma has few treatment options, and the current therapeutic standard of care is dacarbazine which is a highly cytotoxic drug with severe side effects including vomiting, headache and hair loss. Treatmentwith dacarbazine has a median progression-free enhancement of survival time of only 1.5 months. Riluzole (RilutekTM) is a non-toxic drug and the ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  3. Characterization of a GPCR-blocking antibody for the treatment of breast cancer.

    SBC: EXPRESSION DRUG DESIGN LLC            Topic: NCI

    DESCRIPTION (provided by applicant): G protein-coupled receptors (GPCRs) represent a diverse family of cell surface receptors that mediate important biological responses in nearly all cells. These responses include proliferation, migration, tissue invasion, and cell survival. As such, this large, ~700 member family represents the most attractive single family of drug targets for a variety of dise ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  4. Multiparameter Assay for Mechanistic Understanding of Carcinogens

    SBC: PRIMITY BIO, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): The determination of carcinogenic activity in experimental compounds is a long and expensive process that negatively impacts many core industries and can threaten human health. Faster, more reliable methods that can beused to accurately determine human oncogenic activity are needed to rapidly identify environmental problems and reduce the reliance on animal mod ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  5. Development of a Selective PLK2 Inhibitor for Cancer Therapy

    SBC: ONCONOVA THERAPEUTICS, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): The recent success of imatinib for the treatment of Philadelphia chromosome-positive chronic myelogenous leukemia has made tyrosine and serine/threonine kinases as major targets for cancer therapy. Currently, since only a small fraction of the human kinome has been targeted by reasonably selective and potent inhibitors, there is an urgent need to develop stra ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  6. Palliative Care Provider Online Education in Evidence-Based Complementary Therapi

    SBC: COLLINGE AND ASSOCIATES, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): Palliative care represents one of the most rapidly expanding sectors of health care. Its rapid growth has been accompanied by widespread needs for training of multidisciplinary personnel to work with the unique set of health issues specific to its population of patients - not only those at end-of-life, but also patients with long- term, incurable, chronic and d ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  7. Utrasensitive bioassays using palladium catalyzed chemical amplification

    SBC: BIOFORMATIX, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): We propose to use novel Palladium Catalyzed Chemical Amplification (PdCCA) technology to develop ultra-sensitive bioassays that can detect very low concentrations of tumor biomarkers in blood. PdCCA is a generic technology that can be universally applied to different assay platforms. In the bioassay application considered here it uses a detection antibody labe ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  8. HEPylated G-CSF: Drug with Safer, Enhanced Delivery for Neutropenia Treatment

    SBC: CAISSON BIOTECH, LLC            Topic: NCI

    DESCRIPTION (provided by applicant): Poly[ethylene glycol] (PEG) polymers are widely used by pharma to enhance the physical, chemical, and/or biological nature of promising drug candidates. The process of adding PEG polymers to drug cargo is termed PEGylation and has resulted in several Billion/year drugs. PEGylation protects the cargo when in the body and prolongs therapeutic action. For patient ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  9. Modulation of In Vivo Tumor Oxygenation via Polymersome-encapsulated Myoglobin

    SBC: VINDICO NANOBIOTECHNOLOGY, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): Over 250,000 new cases of head and neck cancers (HNCs) and non-small cell lung cancers (NSCLCs) are diagnosed every year in the United States. At the time of diagnosis, 60% of these cases are regionally advanced (stageIII and IV). Wide surgical excision is not the immediate therapeutic option for most of these locally advanced solid tumor malignancies. A number ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  10. Screening of FoxA1-ER-DNA disruptors for development of breast cancer therapeutic

    SBC: Proteovista LLC            Topic: NCI

    DESCRIPTION (provided by applicant): Estrogen receptor a (ERa) is the major therapeutic target for breast cancer, and ERa binding at target genes in breast cancer cells is guided by DNA binding pioneer factor proteins such as FoxA1. Although tamoxifen is asuccessful therapeutic for suppressing ER-mediated gene regulation, resistance to tamoxifen occurs in most breast cancer patients within five ye ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government